Clinical trial
A Single Ascending Dose, Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of SP-101 Via Nebulizer for the Treatment of Cystic Fibrosis (CF)
NCT06526923 is registered in ClinicalTrials.gov with Spirovant Sciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Ascending Dose, Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of SP-101 Via Nebulizer for the Treatment of Cystic Fibrosis (CF)
- Lead sponsor
- Spirovant Sciences, Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 16, 2024
- Completion date
- December 31, 2026
- Enrollment
- 15 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.